The Experts below are selected from a list of 3465 Experts worldwide ranked by ideXlab platform

Russell J Reiter - One of the best experts on this subject based on the ideXlab platform.

  • melatonin as Pharmacologic support in burn patients a proposed solution to thermal injury related lymphocytopenia and oxidative damage
    Critical Care Medicine, 2007
    Co-Authors: Maria D Maldonado, F Murillocabezas, Patricia J Lardone, Juan M. Guerrero, Juan R. Calvo, Russell J Reiter
    Abstract:

    OBJECTIVE: To review the data that support the clinical use of melatonin in the treatment of burn patients, with special emphasis on the stimulation of the oxidative defense system, the immune system, circadian rhythm of sleep/wakefulness, and the reduction in the toxicity of therapeutic Agents used in the treatment of burn victims. DATA SOURCE: A MEDLINE/PubMed search from 1975 to July 2006 was conducted. STUDY SELECTION: The screening of the literature was examined using the key words: burn patients, lymphocytopenia, skin oxidative stress, antioxidant, melatonin, and free radicals. DATA EXTRACTION AND SYNTHESIS: Thermal injury often causes damage to multiple organs remote from the original burn wound and may lead to multiple organ failure. Animal models and burn patients exhibit elevated free radical generation that may be causative in the local wound response and in the development of burn shock and distant organ injury. The suppression of nonspecific resistance and the disturbance in the adaptive immune system makes burn patients vulnerable to infections. Moreover, there is loss of sleep and the toxicity produced by drugs habitually used in the clinic for burn patients. Melatonin is a powerful antioxidant and is a potent protective Agent against damage after experimental thermal injury. Some actions of melatonin as a potential supportive Pharmacologic Agent in burn patients include its: role as a scavenger of both oxygen and nitrogen-based reactants, stimulation of the activities of a variety of antioxidative enzymes, reduction in proinflammatory cytokines, inhibition of adhesion molecules, chronobiotic effects, and reduction in the toxicity of the drugs used in protocols to treat thermal injury patients. CONCLUSIONS: These combined actions of melatonin, along with its low toxicity and its ability to penetrate all morphophysiologic membranes, could make it a ubiquitously acting and highly beneficial molecule in burn patients.

  • melatonin as Pharmacologic support in burn patients a proposed solution to thermal injury related lymphocytopenia and oxidative damage
    Critical Care Medicine, 2007
    Co-Authors: Maria D Maldonado, F Murillocabezas, Patricia J Lardone, Juan M. Guerrero, Juan R. Calvo, Dun Xian Tan, Russell J Reiter
    Abstract:

    Objective: To review the data that support the clinical use of melatonin in the treatment of burn patients, with special emphasis on the stimulation of the oxidative defense system, the immune system, circadian rhythm of sleep/wakefulness, and the reduction in the toxicity of therapeutic Agents used in the treatment of burn victims. Data Source: A MEDLINE/PubMed search from 1975 to July 2006 was conducted. Study Selection: The screening of the literature was examined using the key words: burn patients, lymphocytopenia, skin oxidative stress, antioxidant, melatonin, and free radicals. Data Extraction and Synthesis: Thermal injury often causes damage to multiple organs remote from the original burn wound and may lead to multiple organ failure. Animal models and burn patients exhibit elevated free radical generation that may be causative in the local wound response and in the development of burn shock and distant organ injury. The suppression of nonspecific resistance and the disturbance in the adaptive immune system makes burn patients vulnerable to infections. Moreover, there is loss of sleep and the toxicity produced by drugs habitually used in the clinic for burn patients. Melatonin is a powerful antioxidant and is a potent protective Agent against damage after experimental thermal injury. Some actions of melatonin as a potential supportive Pharmacologic Agent in burn patients include its: role as a scavenger of both oxygen and nitrogen-based reactants, stimulation of the activities of a variety of antioxidative enzymes, reduction in proinflammatory cytokines, inhibition of adhesion molecules, chronobiotic effects, and reduction in the toxicity of the drugs used in protocols to treat thermal injury patients. Conclusions: These combined actions of melatonin, along with its low toxicity and its ability to penetrate all morphophysiologic membranes, could make it a ubiquitously acting and highly beneficial molecule in burn patients. (Crit Care Med 2007;

Maria D Maldonado - One of the best experts on this subject based on the ideXlab platform.

  • melatonin as Pharmacologic support in burn patients a proposed solution to thermal injury related lymphocytopenia and oxidative damage
    Critical Care Medicine, 2007
    Co-Authors: Maria D Maldonado, F Murillocabezas, Patricia J Lardone, Juan M. Guerrero, Juan R. Calvo, Russell J Reiter
    Abstract:

    OBJECTIVE: To review the data that support the clinical use of melatonin in the treatment of burn patients, with special emphasis on the stimulation of the oxidative defense system, the immune system, circadian rhythm of sleep/wakefulness, and the reduction in the toxicity of therapeutic Agents used in the treatment of burn victims. DATA SOURCE: A MEDLINE/PubMed search from 1975 to July 2006 was conducted. STUDY SELECTION: The screening of the literature was examined using the key words: burn patients, lymphocytopenia, skin oxidative stress, antioxidant, melatonin, and free radicals. DATA EXTRACTION AND SYNTHESIS: Thermal injury often causes damage to multiple organs remote from the original burn wound and may lead to multiple organ failure. Animal models and burn patients exhibit elevated free radical generation that may be causative in the local wound response and in the development of burn shock and distant organ injury. The suppression of nonspecific resistance and the disturbance in the adaptive immune system makes burn patients vulnerable to infections. Moreover, there is loss of sleep and the toxicity produced by drugs habitually used in the clinic for burn patients. Melatonin is a powerful antioxidant and is a potent protective Agent against damage after experimental thermal injury. Some actions of melatonin as a potential supportive Pharmacologic Agent in burn patients include its: role as a scavenger of both oxygen and nitrogen-based reactants, stimulation of the activities of a variety of antioxidative enzymes, reduction in proinflammatory cytokines, inhibition of adhesion molecules, chronobiotic effects, and reduction in the toxicity of the drugs used in protocols to treat thermal injury patients. CONCLUSIONS: These combined actions of melatonin, along with its low toxicity and its ability to penetrate all morphophysiologic membranes, could make it a ubiquitously acting and highly beneficial molecule in burn patients.

  • melatonin as Pharmacologic support in burn patients a proposed solution to thermal injury related lymphocytopenia and oxidative damage
    Critical Care Medicine, 2007
    Co-Authors: Maria D Maldonado, F Murillocabezas, Patricia J Lardone, Juan M. Guerrero, Juan R. Calvo, Dun Xian Tan, Russell J Reiter
    Abstract:

    Objective: To review the data that support the clinical use of melatonin in the treatment of burn patients, with special emphasis on the stimulation of the oxidative defense system, the immune system, circadian rhythm of sleep/wakefulness, and the reduction in the toxicity of therapeutic Agents used in the treatment of burn victims. Data Source: A MEDLINE/PubMed search from 1975 to July 2006 was conducted. Study Selection: The screening of the literature was examined using the key words: burn patients, lymphocytopenia, skin oxidative stress, antioxidant, melatonin, and free radicals. Data Extraction and Synthesis: Thermal injury often causes damage to multiple organs remote from the original burn wound and may lead to multiple organ failure. Animal models and burn patients exhibit elevated free radical generation that may be causative in the local wound response and in the development of burn shock and distant organ injury. The suppression of nonspecific resistance and the disturbance in the adaptive immune system makes burn patients vulnerable to infections. Moreover, there is loss of sleep and the toxicity produced by drugs habitually used in the clinic for burn patients. Melatonin is a powerful antioxidant and is a potent protective Agent against damage after experimental thermal injury. Some actions of melatonin as a potential supportive Pharmacologic Agent in burn patients include its: role as a scavenger of both oxygen and nitrogen-based reactants, stimulation of the activities of a variety of antioxidative enzymes, reduction in proinflammatory cytokines, inhibition of adhesion molecules, chronobiotic effects, and reduction in the toxicity of the drugs used in protocols to treat thermal injury patients. Conclusions: These combined actions of melatonin, along with its low toxicity and its ability to penetrate all morphophysiologic membranes, could make it a ubiquitously acting and highly beneficial molecule in burn patients. (Crit Care Med 2007;

Ajay E. Kuriyan - One of the best experts on this subject based on the ideXlab platform.

  • salinomycin inhibits proliferative vitreoretinopathy formation in a mouse model
    PLOS ONE, 2020
    Co-Authors: Alison M Heffer, Ajay E. Kuriyan, Victor Wang, Richard T Libby, Steven E Feldon, Collynn F Woeller
    Abstract:

    Proliferative vitreoretinopathy (PVR) is a progressive disease that develops in a subset of patients who undergo surgery for retinal detachment repair, and results in significant vision loss. PVR is characterized by the migration of retinal pigment epithelial (RPE) cells into the vitreous cavity, where they undergo epithelial-to-mesenchymal transition and form contractile membranes within the vitreous and along the retina, resulting in recurrent retinal detachments. Currently, surgical intervention is the only treatment for PVR and there are no Pharmacological Agents that effectively inhibit or prevent PVR formation. Here, we show that a single intravitreal injection of the polyether ionophore salinomycin (SNC) effectively inhibits the formation of PVR in a mouse model with no evidence of retinal toxicity. After 4 weeks, fundus photography and optical coherence tomography (OCT) demonstrated development of mean PVR grade of 3.5 (SD: 1.3) in mouse eyes injected with RPE cells/DMSO (vehicle), compared to mean PVR grade of 1.6 (SD: 1.3) in eyes injected with RPE cells/SNC (p = 0.001). Additionally, immunohistochemistry analysis showed RPE cells/SNC treatment reduced both fibrotic (αSMA, FN1, Vim) and inflammatory (GFAP, CD3, CD20) markers compared to control RPE cells/DMSO treatment. Finally, qPCR analysis confirmed that Tgfβ, Tnfα, Mcp1 (inflammatory/cytokine markers), and Fn1, Col1a1 and Acta2 (fibrotic markers) were significantly attenuated in the RPE cells/SNC group compared to RPE/DMSO control. These results suggest that SNC is a potential Pharmacologic Agent for the prevention of PVR in humans and warrants further investigation.

  • Proliferative Vitreoretinopathy: A Review
    International ophthalmology clinics, 2019
    Co-Authors: Sana Idrees, Jayanth Sridhar, Ajay E. Kuriyan
    Abstract:

    Proliferative vitreoretinopathy (PVR) is the most common cause for failure of rhegmatogenous retinal detachment repair and is characterized by the growth and contraction of cellular membranes within the vitreous cavity and on both sides of the retinal surface as well as intraretinal fibrosis. Currently, PVR is thought to be an abnormal wound healing response that is primarily driven by inflammatory, retinal, and RPE cells. At this time, surgery is the only management option for PVR as there is no proven Pharmacologic Agent for the treatment or prevention of PVR. Laboratory research to better understand PVR pathophysiology and clinical trials of various Agents to prevent PVR formation are ongoing.

Juan R. Calvo - One of the best experts on this subject based on the ideXlab platform.

  • melatonin as Pharmacologic support in burn patients a proposed solution to thermal injury related lymphocytopenia and oxidative damage
    Critical Care Medicine, 2007
    Co-Authors: Maria D Maldonado, F Murillocabezas, Patricia J Lardone, Juan M. Guerrero, Juan R. Calvo, Russell J Reiter
    Abstract:

    OBJECTIVE: To review the data that support the clinical use of melatonin in the treatment of burn patients, with special emphasis on the stimulation of the oxidative defense system, the immune system, circadian rhythm of sleep/wakefulness, and the reduction in the toxicity of therapeutic Agents used in the treatment of burn victims. DATA SOURCE: A MEDLINE/PubMed search from 1975 to July 2006 was conducted. STUDY SELECTION: The screening of the literature was examined using the key words: burn patients, lymphocytopenia, skin oxidative stress, antioxidant, melatonin, and free radicals. DATA EXTRACTION AND SYNTHESIS: Thermal injury often causes damage to multiple organs remote from the original burn wound and may lead to multiple organ failure. Animal models and burn patients exhibit elevated free radical generation that may be causative in the local wound response and in the development of burn shock and distant organ injury. The suppression of nonspecific resistance and the disturbance in the adaptive immune system makes burn patients vulnerable to infections. Moreover, there is loss of sleep and the toxicity produced by drugs habitually used in the clinic for burn patients. Melatonin is a powerful antioxidant and is a potent protective Agent against damage after experimental thermal injury. Some actions of melatonin as a potential supportive Pharmacologic Agent in burn patients include its: role as a scavenger of both oxygen and nitrogen-based reactants, stimulation of the activities of a variety of antioxidative enzymes, reduction in proinflammatory cytokines, inhibition of adhesion molecules, chronobiotic effects, and reduction in the toxicity of the drugs used in protocols to treat thermal injury patients. CONCLUSIONS: These combined actions of melatonin, along with its low toxicity and its ability to penetrate all morphophysiologic membranes, could make it a ubiquitously acting and highly beneficial molecule in burn patients.

  • melatonin as Pharmacologic support in burn patients a proposed solution to thermal injury related lymphocytopenia and oxidative damage
    Critical Care Medicine, 2007
    Co-Authors: Maria D Maldonado, F Murillocabezas, Patricia J Lardone, Juan M. Guerrero, Juan R. Calvo, Dun Xian Tan, Russell J Reiter
    Abstract:

    Objective: To review the data that support the clinical use of melatonin in the treatment of burn patients, with special emphasis on the stimulation of the oxidative defense system, the immune system, circadian rhythm of sleep/wakefulness, and the reduction in the toxicity of therapeutic Agents used in the treatment of burn victims. Data Source: A MEDLINE/PubMed search from 1975 to July 2006 was conducted. Study Selection: The screening of the literature was examined using the key words: burn patients, lymphocytopenia, skin oxidative stress, antioxidant, melatonin, and free radicals. Data Extraction and Synthesis: Thermal injury often causes damage to multiple organs remote from the original burn wound and may lead to multiple organ failure. Animal models and burn patients exhibit elevated free radical generation that may be causative in the local wound response and in the development of burn shock and distant organ injury. The suppression of nonspecific resistance and the disturbance in the adaptive immune system makes burn patients vulnerable to infections. Moreover, there is loss of sleep and the toxicity produced by drugs habitually used in the clinic for burn patients. Melatonin is a powerful antioxidant and is a potent protective Agent against damage after experimental thermal injury. Some actions of melatonin as a potential supportive Pharmacologic Agent in burn patients include its: role as a scavenger of both oxygen and nitrogen-based reactants, stimulation of the activities of a variety of antioxidative enzymes, reduction in proinflammatory cytokines, inhibition of adhesion molecules, chronobiotic effects, and reduction in the toxicity of the drugs used in protocols to treat thermal injury patients. Conclusions: These combined actions of melatonin, along with its low toxicity and its ability to penetrate all morphophysiologic membranes, could make it a ubiquitously acting and highly beneficial molecule in burn patients. (Crit Care Med 2007;

Juan M. Guerrero - One of the best experts on this subject based on the ideXlab platform.

  • melatonin as Pharmacologic support in burn patients a proposed solution to thermal injury related lymphocytopenia and oxidative damage
    Critical Care Medicine, 2007
    Co-Authors: Maria D Maldonado, F Murillocabezas, Patricia J Lardone, Juan M. Guerrero, Juan R. Calvo, Russell J Reiter
    Abstract:

    OBJECTIVE: To review the data that support the clinical use of melatonin in the treatment of burn patients, with special emphasis on the stimulation of the oxidative defense system, the immune system, circadian rhythm of sleep/wakefulness, and the reduction in the toxicity of therapeutic Agents used in the treatment of burn victims. DATA SOURCE: A MEDLINE/PubMed search from 1975 to July 2006 was conducted. STUDY SELECTION: The screening of the literature was examined using the key words: burn patients, lymphocytopenia, skin oxidative stress, antioxidant, melatonin, and free radicals. DATA EXTRACTION AND SYNTHESIS: Thermal injury often causes damage to multiple organs remote from the original burn wound and may lead to multiple organ failure. Animal models and burn patients exhibit elevated free radical generation that may be causative in the local wound response and in the development of burn shock and distant organ injury. The suppression of nonspecific resistance and the disturbance in the adaptive immune system makes burn patients vulnerable to infections. Moreover, there is loss of sleep and the toxicity produced by drugs habitually used in the clinic for burn patients. Melatonin is a powerful antioxidant and is a potent protective Agent against damage after experimental thermal injury. Some actions of melatonin as a potential supportive Pharmacologic Agent in burn patients include its: role as a scavenger of both oxygen and nitrogen-based reactants, stimulation of the activities of a variety of antioxidative enzymes, reduction in proinflammatory cytokines, inhibition of adhesion molecules, chronobiotic effects, and reduction in the toxicity of the drugs used in protocols to treat thermal injury patients. CONCLUSIONS: These combined actions of melatonin, along with its low toxicity and its ability to penetrate all morphophysiologic membranes, could make it a ubiquitously acting and highly beneficial molecule in burn patients.

  • melatonin as Pharmacologic support in burn patients a proposed solution to thermal injury related lymphocytopenia and oxidative damage
    Critical Care Medicine, 2007
    Co-Authors: Maria D Maldonado, F Murillocabezas, Patricia J Lardone, Juan M. Guerrero, Juan R. Calvo, Dun Xian Tan, Russell J Reiter
    Abstract:

    Objective: To review the data that support the clinical use of melatonin in the treatment of burn patients, with special emphasis on the stimulation of the oxidative defense system, the immune system, circadian rhythm of sleep/wakefulness, and the reduction in the toxicity of therapeutic Agents used in the treatment of burn victims. Data Source: A MEDLINE/PubMed search from 1975 to July 2006 was conducted. Study Selection: The screening of the literature was examined using the key words: burn patients, lymphocytopenia, skin oxidative stress, antioxidant, melatonin, and free radicals. Data Extraction and Synthesis: Thermal injury often causes damage to multiple organs remote from the original burn wound and may lead to multiple organ failure. Animal models and burn patients exhibit elevated free radical generation that may be causative in the local wound response and in the development of burn shock and distant organ injury. The suppression of nonspecific resistance and the disturbance in the adaptive immune system makes burn patients vulnerable to infections. Moreover, there is loss of sleep and the toxicity produced by drugs habitually used in the clinic for burn patients. Melatonin is a powerful antioxidant and is a potent protective Agent against damage after experimental thermal injury. Some actions of melatonin as a potential supportive Pharmacologic Agent in burn patients include its: role as a scavenger of both oxygen and nitrogen-based reactants, stimulation of the activities of a variety of antioxidative enzymes, reduction in proinflammatory cytokines, inhibition of adhesion molecules, chronobiotic effects, and reduction in the toxicity of the drugs used in protocols to treat thermal injury patients. Conclusions: These combined actions of melatonin, along with its low toxicity and its ability to penetrate all morphophysiologic membranes, could make it a ubiquitously acting and highly beneficial molecule in burn patients. (Crit Care Med 2007;